SLC5A2 and hydrops fetalis: In HFpEF, conventional approaches have historically shown limited efficacy; however, recent trials such as EMPEROR-Preserved and DELIVER established that SGLT2 inhibitors significantly reduce HF hospitalizations and cardiovascular death, irrespective of diabetes status, marking a paradigm shift in the management of cardiometabolic HF [78,79].